When comparing patients who initiated treatment with exenatide (n=14,076, median follow-up: 969 days), to those starting dulaglutide (n=54,787, median follow-up: 948 days) or liraglutide (n=25,562, median follow-up: 1,007 days), no differences were found in the hazard of composite treatment for diabetic macular edema (DME) and/or proliferative DR: exenatide vs
On day one of starting semaglutide GLP-1 , most individuals do not experience immediate appetite suppression
Approximately 85 percent of patients report that side effects are mild, temporary, and manageable with support
Reducing the amount of sugar the liver makes The liver produces glucose, especially when a person is fasting
Ready to explore your next step